737 related articles for article (PubMed ID: 15747245)
1. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
2. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.
Wright PF; Karron RA; Madhi SA; Treanor JJ; King JC; O'Shea A; Ikizler MR; Zhu Y; Collins PL; Cutland C; Randolph VB; Deatly AM; Hackell JG; Gruber WC; Murphy BR
J Infect Dis; 2006 Feb; 193(4):573-81. PubMed ID: 16425137
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
[TBL] [Abstract][Full Text] [Related]
4. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
5. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
Wright PF; Karron RA; Belshe RB; Thompson J; Crowe JE; Boyce TG; Halburnt LL; Reed GW; Whitehead SS; Anderson EL; Wittek AE; Casey R; Eichelberger M; Thumar B; Randolph VB; Udem SA; Chanock RM; Murphy BR
J Infect Dis; 2000 Nov; 182(5):1331-42. PubMed ID: 11010838
[TBL] [Abstract][Full Text] [Related]
7. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
[TBL] [Abstract][Full Text] [Related]
8. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
9. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo.
Jin H; Zhou H; Cheng X; Tang R; Munoz M; Nguyen N
Virology; 2000 Jul; 273(1):210-8. PubMed ID: 10891423
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
[TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children.
Karron RA; Luongo C; Mateo JS; Wanionek K; Collins PL; Buchholz UJ
J Infect Dis; 2020 Jun; 222(1):82-91. PubMed ID: 31605113
[TBL] [Abstract][Full Text] [Related]
12. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
Whitehead SS; Firestone CY; Collins PL; Murphy BR
Virology; 1998 Aug; 247(2):232-9. PubMed ID: 9705916
[TBL] [Abstract][Full Text] [Related]
13. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
14. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
Buchholz UJ; Cunningham CK; Muresan P; Gnanashanmugam D; Sato P; Siberry GK; Rexroad V; Valentine M; Perlowski C; Schappell E; Thumar B; Luongo C; Barr E; Aziz M; Yogev R; Spector SA; Collins PL; McFarland EJ; Karron RA;
J Infect Dis; 2018 Apr; 217(9):1338-1346. PubMed ID: 29509929
[TBL] [Abstract][Full Text] [Related]
15. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.
Connors M; Crowe JE; Firestone CY; Murphy BR; Collins PL
Virology; 1995 Apr; 208(2):478-84. PubMed ID: 7747420
[TBL] [Abstract][Full Text] [Related]
16. Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates.
Lin YH; Deatly AM; Chen W; Miller LZ; Lerch R; Sidhu MS; Udem SA; Randolph VB
Virus Res; 2006 Jan; 115(1):9-15. PubMed ID: 16099066
[TBL] [Abstract][Full Text] [Related]
17. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
18. In search of a vaccine for respiratory syncytial virus: the saga continues.
Englund J
J Infect Dis; 2005 Apr; 191(7):1036-9. PubMed ID: 15747236
[No Abstract] [Full Text] [Related]
19. Advances in respiratory syncytial virus vaccine development.
Kneyber MC; Kimpen JL
Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
[TBL] [Abstract][Full Text] [Related]
20. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
